Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023647 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV Melanoma
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00023647: Completed Phase 1 study, sponsored by Mannkind Corporation.
NCT00023647 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023647, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given directly into a lymph node in treating patients who have stage IV melanoma.
Interventions
- BIOLOGICAL Synchrotope TA2M
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2000-07 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
What the finished NCT00023647 record still lists
NCT00023647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Synchrotope TA2M is the first listed.
NCT00023647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00023647 about?
NCT00023647 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given directly into a lymph node i...
What is the current status of trial NCT00023647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2000-07. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00023647?
The interventions under investigation include: Synchrotope TA2M (BIOLOGICAL).
Who is sponsoring clinical trial NCT00023647?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00023647's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia